The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2021 | Future directions in MPN therapy
Laura Michaelis, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the future of myeloproliferative neoplasm (MPN) therapy and the implications for patients with MPNs. Dr Michaelis explains that more data is expected to be seen from trials investigating novel agents such as IDH-1/2 inhibitors and BCL-2 inhibitors, agents which have already received approval for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia. Dr Michaelis further talks on the prospects of immunotherapy for myelofibrosis and other advanced MPNs. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
